A multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of WelChol [colesevelam] in type 2 diabetics with inadequate glycemic control on metformin monotherapy or metformin therapy in combination with other oral anti-diabetic agents.

Trial Profile

A multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of WelChol [colesevelam] in type 2 diabetics with inadequate glycemic control on metformin monotherapy or metformin therapy in combination with other oral anti-diabetic agents.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Colesevelam (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Jan 2012 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
    • 13 Oct 2008 Results published in the Archives of Internal Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top